Agentix Corp., a clinical-stage biotechnology company focused on developing therapeutic agents for metabolic diseases such as Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH), has released its Form 10-Q report for the quarter ended December 31, 2025. The report provides a detailed overview of the company's financial performance and operational challenges.
Financial Highlights
Total Revenue: $0 million. The company recorded no revenues during the three and nine months ended December 31, 2025, and 2024.
Net (loss) income: $(78,595) for the three months ended December 31, 2025, compared to $(143,894) for the same period in 2024, reflecting a reduction in net loss.
Net (loss) income: $(408,526) for the nine months ended December 31, 2025, compared to $(385,280) for the same period in 2024, indicating an increase in net loss.
Loss per share - Basic and diluted: $(0.00) for the three months ended December 31, 2025, consistent with the same period in 2024.
Loss per share - Basic and diluted: $(0.01) for the nine months ended December 31, 2025, consistent with the same period in 2024.
Professional fees: $50,678 for the three months ended December 31, 2025, a decrease from $56,632 in the same period in 2024, mainly due to lower accounting and consulting fees.
Professional fees: $214,536 for the nine months ended December 31, 2025, an increase from $197,942 in the same period in 2024, mainly due to higher accounting, legal, and consulting support.
Research and development expenses: $0 for the three months ended December 31, 2025, compared to $23,287 in the same period in 2024, reflecting a decrease in R&D consulting costs.
Research and development expenses: $125,079 for the nine months ended December 31, 2025, compared to $90,638 in the same period in 2024, reflecting increased R&D consulting and project activity.
General and administrative expenses: $16,785 for the three months ended December 31, 2025, a slight decrease from $16,896 in the same period in 2024, primarily due to lower software and other administrative costs.
General and administrative expenses: $51,287 for the nine months ended December 31, 2025, a decrease from $52,550 in the same period in 2024, reflecting cost controls and lower software and overhead expenses.
Foreign exchange gain (loss): $2,672 gain for the three months ended December 31, 2025, compared to a $35,784 loss in the same period in 2024, due to fluctuations in currency exchange rates.
Foreign exchange gain (loss): $20,961 gain for the nine months ended December 31, 2025, compared to a $15,376 loss in the same period in 2024, due to currency fluctuations.
Interest expense, net: $13,804 for the three months ended December 31, 2025, compared to $11,295 in the same period in 2024, related to higher average borrowings and related financing costs.
Interest expense, net: $59,189 for the nine months ended December 31, 2025, compared to $28,774 in the same period in 2024, related to higher average debt balances and related financing costs.
Business Highlights
Company Overview: Agentix Corp. is a clinical-stage biotechnology company focused on developing therapeutic agents for metabolic diseases such as Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
Operational Challenges: The company faces significant operational challenges due to its accumulated deficit, net loss, negative cash flows from operating activities, and negative working capital, raising substantial doubt about its ability to continue as a going concern.
Research and Development: For the nine months ended December 31, 2025, research and development expenses increased to $125,079 from $90,638 in the same period in 2024, primarily due to increased R&D consulting and project activity.
Professional Fees: Professional fees for the nine months ended December 31, 2025, were $214,536, up from $197,942 in the same period in 2024, driven by higher accounting, legal, and consulting support.
General and Administrative Expenses: These expenses slightly decreased to $51,287 for the nine months ended December 31, 2025, from $52,550 in the same period in 2024, reflecting cost controls and lower software and overhead expenses.
Foreign Exchange Impact: The company experienced a foreign exchange gain of $20,961 for the nine months ended December 31, 2025, compared to a loss of $15,376 in the same period in 2024, due to currency fluctuations.
Interest Expense: Interest expense increased significantly to $59,189 for the nine months ended December 31, 2025, from $28,774 in the same period in 2024, related to higher average debt balances and related financing costs.
Future Outlook: The company is attempting to commence operations and generate sufficient revenue, but its current cash position is insufficient to support daily operations. It will need to raise funds through equity or debt financing to continue its operations and development activities.
SEC Filing: